Journal profile · Medicine-Pharmacology (medical)
Therapeutic Advances in Drug Safety
ISSN 2042-0986 · eISSN 2042-0994 · SAGE · ENGLAND
Therapeutic Advances in Drug Safety: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.17; fully open access; APC about USD 2,800; median 153 days to acceptance (98 articles, last 24 months); acceptance rate 17.9% (journal website); 68 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Therapeutic Advances in Drug Safety is published by SAGE and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical Practices and Patient Outcomes and Patient Safety and Medication Errors, together about 43.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
Source: LetPub
Research area (LetPub): Medicine-Pharmacology (medical)
Editor-in-chief Arduino MangoniPublisher website
Editorial board by country: none in mainland China; most named United States 23, United Kingdom 20, Australia 14, Italy 6, Canada 3 (100 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics19.5%
- Pharmaceutical Practices and Patient OutcomesMedicine17%
- Patient Safety and Medication ErrorsHealth Professions6.8%
- Medication Adherence and ComplianceMedicine5.6%
- Pharmaceutical studies and practicesMedicine5.5%
- Atrial Fibrillation Management and OutcomesMedicine3.6%
- Drug-Induced Adverse ReactionsMedicine3.2%
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.17LetPub ·
- Impact factor (publisher)
- 3.3Publisher website ·
- 5-year impact factor (publisher)
- 4.2Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.83LetPub ·
- SNIP 2026-06
- 1.31LetPub ·
- h-index
- 65OpenAlex ·
- i10-index
- 315OpenAlex ·
- 2-year mean citedness
- 3.93OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 64LetPub ·
Articles by year OpenAlex count · 614 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 59 | 59 | 36 |
| 2025 | 68 | 68 | 310 |
| 2024 | 51 | 51 | 353 |
| 2023 | 28 | 28 | 291 |
| 2022 | 35 | 35 | 676 |
| 2021 | 38 | 38 | 726 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
153 daysMedian, submission to acceptance · P25–P75 119 days – 194 days
- Acceptance to online
- median 32 days (99 articles)
- Submission to online
- median 186 days
- Sample
- 98 articles with submission and acceptance dates (137 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 9 weeksLetPub ·
- Acceptance rate (publisher)
- 17.9%Publisher website ·
- Submission to first decision
- 2 daysPublisher website ·
- Acceptance to publication
- 31 daysPublisher website ·
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,800 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,800 | — | — | |
| LetPub | USD 2,800 | Yes | — | |
| Publisher website | USD 3,200 / USD 5,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- original research articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Therapeutic Advances in Drug Safety is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, p…
Source ↗Publisher website ·- Peer review Peer review policy
The following summary describes the peer review process for this journal: Identity transparency: Single Anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2042-0986
- Electronic ISSN
- 2042-0994
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Therapeutic Advances in Drug Safety
What CAS zone is Therapeutic Advances in Drug Safety in?
In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutic Advances in Drug Safety is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Therapeutic Advances in Drug Safety?
The latest impact factor listed by LetPub is 3.17; CiteScore 4.6, h-index 65.
How long does peer review take at Therapeutic Advances in Drug Safety?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 153 days (interquartile range 119–194 days); authors report an average review time of about 9 weeks; the journal's website gives an acceptance rate of 17.9%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutic Advances in Drug Safety based?
Of the 100 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (23), United Kingdom (20) and Australia (14). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutic Advances in Drug Safety?
According to LetPub and DOAJ records, Therapeutic Advances in Drug Safety is indexed in SCIE, Scopus and DOAJ.
Is Therapeutic Advances in Drug Safety open access, and what is the APC?
Therapeutic Advances in Drug Safety is a fully open-access journal. APC about USD 2,800.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .